Efficacy Study of Latanoprost and Bimatoprost Solutions in Promoting Eyelash Growth in Patients With Alopecia Areata
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00187577|
Recruitment Status : Completed
First Posted : September 16, 2005
Last Update Posted : June 9, 2011
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Alopecia Areata||Drug: Latanoprost (Xalatan) Drug: Bimatoprost (Lumigan) Drug: Topical application of latanoprost solution to eyelid||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||14 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Single (Outcomes Assessor)|
|Official Title:||Efficacy and Safety of Latanoprost (Xalatan) and Bimatoprost (Lumigan) Ophthalmic Solutions in Promoting Eyelash Growth in Patients With Alopecia Areata|
|Study Start Date :||June 2005|
|Actual Primary Completion Date :||February 2006|
|Actual Study Completion Date :||March 2006|
Active Comparator: application to eyelid of latanoprost solution
Subject will apply latanoprost solution with applicator daily to affected eye lid(s)
Drug: Latanoprost (Xalatan)
Drug: Topical application of latanoprost solution to eyelid
Subject will apply latanoprost to affected eyelid with cotton-tipped applicator daily.
Other Name: Latanoprost (Xalatan)
Active Comparator: Application of bimatoprost to eyelid
Subject will apply bimatoprost solution with applicator daily to affected eye lid(s)
Drug: Bimatoprost (Lumigan)
Bimatoprost solution will be applied to affected eyelid(s) with cotton-tipped applicator daily.
Other Name: Bimatoprost 0.03% solution (Lumigan)
- Eyelash growth in response to topical application of latanoprost or bimatoprost to the eyelid margins of patients with alopecia areata; eyelid photographs and eyelash length will be documented at 8 week intervals. [ Time Frame: 16 weeks ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years to 70 Years (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||Yes|
- Males and females in good general health, ages 18-70.
- Patients with alopecia areata who have had 50% or more eyelash loss for 6 months or longer.
- Any pre-existing eye disorder that would preclude use of a topical agent around the eyes (e.g. infection, inflammation, recent surgery.)
- Subjects with limited close vision who cannot see their eyelid margin clearly.
- Immunosuppressed state.
- Women who are pregnant or who are trying to become pregnant, or are breast-feeding.
- Patients with known allergy to latanoprost or bimatoprost, other prostaglandin F-2a or related drugs, or to benzalkonium.
- Unable to read or follow instructions.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00187577
|United States, California|
|University of California, San Francisco|
|San Francisco, California, United States, 94117|
|Principal Investigator:||Vera H. Price, M.D.||Professor, University of California, San Francisco Department of Dermatology|
|Principal Investigator:||Robert L. Stamper, M.D.||Professor, University of California, San Francisco Department of Ophthalmology|
|Responsible Party:||Robert Stamper, MD, University of California, San Francisco|
|Other Study ID Numbers:||
|First Posted:||September 16, 2005 Key Record Dates|
|Last Update Posted:||June 9, 2011|
|Last Verified:||June 2011|
Pathological Conditions, Anatomical